Griseofulvin is an antifungal antibiotic used primarily in the treatment of dermatophyte infections affecting the skin, hair, and nails. It was first discovered in 1939 from species of the genus Penicillium, highlighting the therapeutic potential of naturally derived compounds. Griseofulvin gained clinical importance in the 1950s when it was introduced for the oral treatment of fungal infections. Unlike topical agents, it works systemically by inhibiting fungal cell mitosis and keratin binding. This unique mechanism made it especially effective for persistent and deep-seated dermatophyte infections. Over time, griseofulvin became a standard therapy for conditions such as ringworm and tinea infections. Its development marked a significant advancement in antifungal pharmacotherapy. Despite newer antifungals being available today, griseofulvin remains an important historical milestone in antifungal treatment.
BRAND NAMES
Gris-PEG: A common brand for the ultramicrosize formulation.
Grifulvin V: A well-known brand for the microsize formulation (note: availability may vary by region).
Fulvicin P/G and Fulvicin-U/F: Frequently prescribed brands in several countries.
Grisactin: A standard brand name for Griseofulvin in various markets.
